Camlin Fine Sciences Ltd

- No explicit mention of any planned new fundraising through debt or equity for the near future. - Company recently completed a rights issue raising Rs. 224 crores. - Out of the rights issue proceeds, Rs. 100 crores have been used to repay existing loans, Rs. 68 crores reserved for further debt repayment, and Rs. 56 crores for general corporate purposes. - Gross debt is currently around Rs. 600 crores, roughly stable over last two years. - Annual debt repayment plan is about Rs. 45-50 crores for FY26, with no accelerated repayment planned. - No indication of additional fundraising beyond the rights issue as of the call date.

- FY26 CAPEX plan is approximately Rs. 30 crores to Rs. 35 crores, primarily for maintenance purposes. - No mention of major incremental CAPEX projects beyond maintenance for the next year. - Focus on scaling new value-added products, especially in Vanillin variants and blends, indicating strategic investment in product portfolio expansion rather than heavy capital expenditure. - Integration of Vitafor Invest NV completed, with strategic emphasis on growing its animal feed business by 20%-25% in FY26 and continued growth thereafter. - No specific new large-scale capacity expansion disclosed, but blends business can be further expanded without significant capacity constraints.

- Blends business is expected to grow at 15-20% annually over the next few years, driven by new customer acquisitions across all geographies (~20% growth projected for FY26). - Vanillin production is targeted to reach 75% capacity utilization in FY26, with a plan to ramp up to 100% by FY27. - The Vanillin business aims for cost reduction (~10% at full utilization) and improved realizations due to price increases and likely anti-dumping actions. - Vitafor acquisition integration is complete, with expectations to grow that animal feed business by 20-25% in FY26 and maintain 20% growth thereafter. - Overall, company expects continued growth across its three verticals: Vanillin, Aroma, and Blends, focusing on expanding product portfolio and scaling up value-added products.

- Blends business expected to grow at 15%-20% annually for next few years, driven by strong demand across geographies and new customer acquisition. - Vanillin plant utilization targeted to reach 75% in FY26 and 100% by FY27, leading to improved cost efficiency and margins. - Cost of Vanillin production expected to reduce by ~10% at full utilization, boosting EBITDA per kg to around $3 (at $11 price). - EBITDA from continuing operations around Rs. 70 crores currently (Q3FY25) expected to become visible steadily; discontinued operations losses to reduce by Q2 FY26. - European plant losses expected to reduce from ~Rs. 55 crores annually to Rs. 20-25 crores after winding down diphenol activity by FY26. - CAPEX planned at Rs. 30-35 crores in FY26, primarily maintenance. - Overall outlook shows stable to improving earnings amid market stabilizations and tariff clarity.

- Current contracted orders are running out in Q4 of FY25. - From Q1 of FY26, there are very few contracted orders currently. - Discussions are ongoing to secure new contracts, especially in the US, due to increased certainty from anti-dumping measures. - In Europe, contracting is still uncertain as the anti-dumping duty quantum and timing are unclear, expected around June. - Optimal pricing and full volume visibility are anticipated post-final order expected in July FY26.